Vorbipiprant (CR6086) is an EP4 receptor antagonist used as a targeted immunomodulator; it is also a potential immune checkpoint inhibitor capable of converting cold tumors into hot tumors; it antagonizes PGE2-stimulated cAMP production (IC50 = 22 nM); it exhibits significant DMARD effects in rodents and demonstrates anti-inflammatory activity by inhibiting immune-mediated inflammatory diseases.